The Striders Impex IPO GMP is currently one of the key discussion points among SME IPO investors. Striders Impex Limited is launching its SME book-build issue worth ₹36.29 crore, and investors are closely watching the grey market trends, valuation metrics, and financial performance before applying.

In this detailed IPO analysis, we cover the Striders Impex IPO GMP today, price band, financials, strengths, weaknesses, lot size, and allotment details to help you make an informed investment decision.

Striders Impex IPO GMP Today

As of 23 February 2026, the Striders Impex IPO GMP stands at ₹0.

• IPO Price Band: ₹71 – ₹72 per share

• Latest GMP: ₹0

• Expected Listing Gain: Neutral (based on current GMP)

A GMP of zero indicates cautious grey market sentiment. However, GMP can change closer to the listing date depending on subscription demand and market conditions.

Striders Impex IPO Dates & Key Details

Issue Structure

• Issue Size: ₹36.29 Crore

• Fresh Issue: 42,78,400 shares (₹32.62 Cr)

• Offer for Sale: 5,08,800 shares (₹3.66 Cr)

• Total Shares: 50,40,000 shares

• Face Value: ₹10 per share

• Issue Type: Book Build Issue

Company Overview – Striders Impex Limited

Striders Impex Limited operates in the toys and children’s consumer goods segment, focusing on:

• Brand collaborations & licensing

• Product sourcing & manufacturing coordination

• Distribution across retail networks

• Direct-to-consumer sales through e-commerce

The company offers a wide range of products including:

• School bags

• Water bottles & lunch boxes

• Plush toys & interactive toys

• Stationery & activity kits

• Licensed character merchandise

• Proprietary branded goods

It follows an asset-light business model, relying on third-party manufacturing while focusing on brand building and distribution.

Striders Impex IPO Lot Size Details

Retail investors must apply for a minimum of 2 lots, as this is an SME IPO.

Financial Performance

Key Financial Highlights (₹ in Crores)

While revenue declined in FY25 compared to FY24, profitability remains stable, and net worth has improved significantly over the past three years.

Key Valuation Metrics

• EPS (FY25): ₹6.27

• P/E Ratio: 11.48x

• ROCE: 57.96%

• RoNW: 55.81%

• Debt/Equity: 1.36

• PAT Margin: 13.59%

• EBITDA Margin: 15.07%

• Price to Book Value: 6.49

At a P/E of 11.48x, the IPO appears reasonably priced compared to SME standards, especially considering strong return ratios.

Objectives of the Issue

The company plans to utilize IPO proceeds for:

• Working capital funding – ₹10 Cr

• Investment in UAE subsidiary (Striders FZ LLC) – ₹4.50 Cr

• Investment in new UAE mainland subsidiary – ₹6.50 Cr

• Loan repayment – ₹3 Cr

• General corporate purposes

Expansion into UAE markets indicates international growth ambitions.

Strengths of Striders Impex IPO

✔ Asset-light business model
✔ Strong licensing partnerships
✔ High ROCE & RoNW
✔ Growing e-commerce presence
✔ Strategic expansion into global markets

Risks & Weaknesses

⚠ Heavy reliance on third-party manufacturing
⚠ High working capital requirements
⚠ Dependence on licensing agreements
⚠ Revenue volatility seen in FY25

Investors must evaluate working capital pressure and debt levels before investing.

Promoter & Shareholding Pattern

• Pre-Issue Promoter Holding: 95.49%

• Post-Issue Promoter Holding: 69.52%

The promoter stake dilution is significant but still maintains strong control post-issue.

Dividend Policy

The company has not declared any dividend in the last three financial years, indicating reinvestment focus for growth.

Striders Impex IPO GMP Analysis – Should You Apply?

The current Striders Impex IPO GMP of ₹0 suggests neutral grey market sentiment. However, GMP alone should not be the sole factor for investment decisions.

Positive Factors:

• Strong profitability ratios

• Reasonable P/E valuation

• Expanding international footprint

• Licensing-driven brand portfolio

Concern Areas:

• Decline in FY25 revenue

• High working capital dependency

• SME IPO liquidity risk

Final Verdict

The Striders Impex IPO GMP currently indicates cautious market sentiment. With a P/E of 11.48x and strong return ratios (ROCE 57.96%, RoNW 55.81%), the IPO appears fairly valued.

This IPO may suit moderate risk investors who understand SME volatility and are looking for growth-oriented consumer brand exposure. Conservative investors may prefer to wait for listing clarity.

https://www.finowings.com/IPO/striders-impex-ipo